Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
      Description

      To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

      Conditions
      Advanced Solid TumorsKirsten Rat Sarcoma (KRAS) pG12C Mutation
      Talk to us
      ACTIVE_NOT_RECRUITING
      Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
      Description

      The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

      Conditions
      Colorectal Cancer (CRC)
      Talk to us